Recce Pharmaceuticals Ltd. RCE

Two of healthcare’s most pressing challenges - the growing prevalence of diabetes and rising antibiotic resistance - are converging in diabetic foot infections, where slow-healing wounds can develop into serious infections, hospitalisation and amputation. The International Diabetes Federation...

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has secured Australian Human Research Ethics Committee (HREC) approval for a further protocol amendment to its pivotal Phase 3 trial of RECCE® 327 Topical Gel (R327G), adding a 208-patient active-controlled study arm in diabetic foot infections...

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) is positioned to benefit from a new five-year, US$66.9 billion US Government strategy aimed at strengthening national defences against pandemics, antimicrobial resistance and other major biological threats. The strategy identifies broad-spectrum...

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) advanced its diabetic foot infection treatment toward commercialisation during the June quarter, securing approval to expand an Australian study into a pivotal Phase 3 trial while progressing a proposed 10-year licensing agreement across the Middle...

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has extended the closing date of its share purchase plan (SPP) to 5:00pm AEST on Friday, July 24, giving eligible shareholders additional time to participate. The SPP allows eligible investors to acquire up to A$30,000 worth of new fully paid...

Recce Pharmaceuticals Ltd CEO James Graham talked with Proactive about the company’s strengthened intellectual property position in Southeast Asia following the grant of a Vietnamese patent covering its RECCE® 327 and RECCE® 529 synthetic anti-infective candidates. The Family 4 patent, granted by the Intellectual Property Office of Vietnam, provides protection until 2041 and represents the eighth patent secured by Recce Pharmaceuticals within this patent family. Graham explained that the patent covers the preparation and manufacture of the company’s compounds, as well as the use of R327 and R5

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has strengthened its intellectual property position in Southeast Asia after securing a Vietnamese patent covering its RECCE® 327 and RECCE® 529 anti-infective candidates. The Family 4 patent, granted by the Intellectual Property Office of...

The S&P/ASX Small Ordinaries Index (ASX:XSO) slipped 25.1 points, or 0.74%, to 3,367.6, extending its five-day decline to 1.68% as weakness across the small-cap sector continued despite a steady stream of positive company announcements. Even as the broader index retreated, several...

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has strengthened its balance sheet with the receipt of a A$3.67 million income tax refund from the Australian Taxation Office (ATO), adding further non-dilutive funding as the company advances its synthetic anti-infective pipeline toward key Phase 3...

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has raised A$4 million to support commercial licensing activity, clinical trials and regulatory-enabling work for its synthetic anti-infective pipeline. The placement, priced at A$0.40 per share, comprises 10.0 million new fully paid ordinary...

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has secured Human Research Ethics Committee (HREC) approval to advance its Australian clinical trial of RECCE® 327 Topical Gel (R327G) for diabetic foot infections (DFI) to a pivotal Phase 3 study, marking a key step in the company’s global...